X IBD's unique rating identifies market leadership with a 1 (worst) to 99 (best) score. The score shows how a stock's price performance over the last 52 weeks stacks up against all the other stocks in our database.

Decades of market research shows that the best stocks tend to have an RS Rating north of 80 in the early stages of their moves.

Adamas Pharmaceuticals has moved more than 5% past a 19.60 entry in a first-stage consolidation, meaning it's now out of a proper buy range. Look for the stock to offer a new buying opportunity like a three-weeks tight or pullback to the 50-day or 10-week moving average.

Adamas Pharmaceuticals posted negative growth for both sales and earnings last quarter. The company is expected to report its next quarterly numbers on or around Nov. 3.

The company earns the No. 144 rank among its peers in the Medical-Biomed/Biotech industry group. Celgene (CELG), Corcept Therapeutics (CORT) and Ligand Pharmaceuticals (LGND) are among the top 5 highly rated stocks within the group.

Notice: Information contained herein is not and should not be construed as an offer, solicitation, or recommendation to buy or sell securities. The information has been obtained from sources we believe to be reliable; however no guarantee is made or implied with respect to its accuracy, timeliness, or completeness. Authors may own the stocks they discuss. The information and content are subject to change without notice.